免疫细胞:在代谢产物和阿尔茨海默病中介
Erdong Zhang1,2,3, Fengqiu Dai4, Ling Tao1,2,3
1The Key Laboratory of Optimal Utilization of Natural Medicine Resources, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, Guizhou, China.
Journal of Alzheimer's disease : JAD
|January 29, 2025
概括
免疫细胞和代谢物显著影响阿尔茨海默病 (AD) 风险. 特定的代谢物-免疫细胞相互作用,如胺/酸盐比率和同类氨酸,增加AD风险,而另一些则提供保护.
科学领域:
- 神经免疫学 神经免疫学
- 代谢学 代谢学 代谢学
- 遗传学 是一个遗传学.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其潜在机制尚不清楚.
- 遗传,环境和生活方式因素都与阿尔茨海默病的发病有关.
研究的目的:
- 为了研究代谢物和免疫细胞激活在阿尔茨海默氏症 (AD) 病因学中的相互作用.
- 为了确定这些相互作用对AD风险的影响.
主要方法:
- 全基因组关联研究 (GWAS) 数据分析.
- 单变异和多变异的门德尔随机化 (MR) 用于731种免疫细胞类型,1400种代谢物和大量队列 (10,520例AD病例,401,661例对照).
- 评估免疫细胞的双向关系和调解作用.
主要成果:
- 希斯蒂丁/酸盐比率和同素与AD风险的积极关联,由免疫细胞介导.
- 防护协会对AD由4-基库马林和硫酸甘酸甲酸盐.
- 特定的免疫细胞标记物 (例如,单细胞上的CD64,CD14+CD16-单细胞上的HLA DR) 与较高的AD风险相关,而其他 (例如,CD33dim HLA DR+CD11b-髓状细胞,CD8+T细胞上的HLA DR) 则具有保护作用.
结论:
- 免疫细胞在阿尔茨海默病 (AD) 发病过程中发挥着关键作用.
- 特定代谢物和免疫细胞之间的相互作用显著影响AD风险.
相关概念视频
01:26Alzheimer's Disease: Overview
439
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
439
01:23Role of Neurotransmitters in Memory
404
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
404
01:22Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160